Identifying minor histocompatibility antigens to improve outcomes in graft-versus-host disease
Systematic identification of minor histocompatibility antigens to address GVHD
This study is looking to help people getting stem cell transplants by finding out which tiny genetic differences between donors and patients might cause complications like graft-versus-host disease, so that doctors can choose the best donors and create personalized treatment plans to keep patients healthier after their transplant.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11056136 on NIH RePORTER |
What this research studies
This research focuses on improving the outcomes of patients undergoing allogeneic hematopoietic stem cell transplantation by identifying minor histocompatibility antigens (mHAgs) that can trigger graft-versus-host disease (GvHD). By analyzing the DNA of both donors and recipients, the study aims to create a personalized risk assessment for GvHD based on the specific genetic differences between them. The researchers will utilize advanced sequencing techniques and computational tools to systematically identify these antigens, which could lead to better donor selection and tailored immunosuppression strategies post-transplant. This approach seeks to reduce the incidence and severity of GvHD, ultimately improving patient survival and quality of life.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients undergoing allogeneic hematopoietic stem cell transplantation who are at risk for developing graft-versus-host disease.
Not a fit: Patients who are not undergoing stem cell transplantation or those who have already developed severe graft-versus-host disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective prevention strategies for graft-versus-host disease, enhancing patient outcomes after stem cell transplantation.
How similar studies have performed: Previous research has shown promise in identifying minor histocompatibility antigens, but this approach aims to refine and personalize the methodology, making it a novel advancement in the field.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Keskin, Derin B — Dana-Farber Cancer Inst
- Study coordinator: Keskin, Derin B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.